Breaking Finance News

Abbott Laboratories (NYSE:ABT) target bumped up to $60.00, released a ratings update earlier today by RBC Capital Markets

RBC Capital Markets upped the price target of Abbott Laboratories (NYSE:ABT) to $60.00 stating a potential upside of 0.07%.

Yesterday Abbott Laboratories (NYSE:ABT) traded 1.29% higher at $55.92. The company’s 50-day moving average is $52.94 and its 200-day moving average is $48.37. The last closing price is up 15.29% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 9,044,529 shares of the stock traded hands, up from an average trading volume of 5,609,800

See Chart Below

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories has a 52 week low of $37.38 and a 52 week high of $56.60 with a P/E ratio of 78.11 The company’s market cap is currently $0.

In addition to RBC Capital Markets reporting its target price, a total of 15 firms have reported on ABT. The one year target is $46.73 with six analysts rating the stock a strong buy, 8 brokerages rating the stock a buy, six brokerages rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.